Lipopeptide antibiotics for XDR Gram-negative infections

多粘菌素是一类药物，被认为是耐多药（MDR）和极耐药（XDR）革兰氏阴性感染的最后治疗选择。不幸的是，对这些抗生素的耐药性正在迅速发展，没有有效的治疗方法，并导致患者死亡。本项目旨在开发一种与多粘菌素相比具有优越的作用谱和更高的安全性的抗生素，并具有抗多粘菌素耐药菌的活性。

The polymyxins are a drug class considered to be a last-resort treatment option for multidrug-resistant (MDR) and extremely drug resistant (XDR) Gram-negative infections. Unfortunately resistance is rapidly developing against these antibiotics, leaving no effective therapies and resulting in patient death. This project aims to develop an antibiotic with superior spectra of action and improved safety profiles compared to the polymyxins, with activity against polymyxin-resistant bacteria.